Aquestive Therapeutics financials
$4.67−1.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M | $45.8M | $52.6M | $67.4M |
| Gross profit | $26.0M | $39.7M | $29.8M | $28.3M | $35.8M | $32.9M | $32.2M | $46.4M |
| Gross margin | 58.3% | 69.0% | 58.8% | 59.3% | 70.5% | 71.7% | 61.3% | 68.9% |
| Operating income | -$76.8M | -$36.2M | -$15.1M | -$42.1M | -$34.7M | -$42.9M | -$52.7M | -$48.9M |
| Net income | -$83.8M | -$44.1M | -$7.9M | -$54.4M | -$70.5M | -$55.8M | -$66.2M | -$61.4M |
| Net margin | −188.1% | −76.7% | −15.6% | −114.1% | −138.8% | −121.7% | −125.9% | −91.0% |
| Diluted EPS | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | $-2.61 | $-2.96 |
| EBITDA | -$76.2M | -$35.5M | -$13.8M | -$39.7M | -$31.7M | -$39.5M | -$49.8M | -$45.7M |
| Operating cash flow | -$52.4M | -$35.8M | -$6.4M | -$9.8M | -$33.0M | -$45.5M | -$60.2M | -$13.0M |
| Free cash flow | -$53.0M | -$35.9M | -$7.4M | -$10.8M | -$33.9M | -$46.0M | -$60.9M | -$14.8M |
| Diluted shares | 106.9M | 86.7M | 61.3M | 48.7M | 38.1M | 33.7M | 25.4M | 20.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $121.2M | $71.5M | $23.9M | $27.3M | $28.0M | $31.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $37.5M | $32.5M | $27.5M | $52.1M | $53.6M | $36.9M |
| Total assets | $160.4M | $101.4M | $57.4M | $57.1M | $62.0M | $62.9M |
| Total liabilities | $194.1M | $161.6M | $163.9M | $175.6M | $144.1M | $111.4M |
| Shareholders' equity | -$33.7M | -$60.2M | -$106.5M | -$118.6M | -$82.1M | -$48.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology